Intuitive Surgical (NASDAQ:ISRG) Given New $421.00 Price Target at BTIG Research

Intuitive Surgical (NASDAQ:ISRG) had its price target hoisted by BTIG Research from $412.00 to $421.00 in a research note released on Friday, Benzinga reports. The brokerage currently has a buy rating on the medical equipment provider’s stock.

ISRG has been the topic of several other reports. Barclays upped their price target on shares of Intuitive Surgical from $385.00 to $430.00 and gave the company an overweight rating in a report on Thursday, January 25th. Mizuho increased their target price on shares of Intuitive Surgical from $350.00 to $390.00 and gave the stock a neutral rating in a research note on Thursday, January 25th. Wells Fargo & Company increased their target price on shares of Intuitive Surgical from $363.00 to $416.00 and gave the stock an overweight rating in a research note on Friday, January 19th. StockNews.com lowered shares of Intuitive Surgical from a buy rating to a hold rating in a research note on Thursday, February 29th. Finally, Stifel Nicolaus increased their target price on shares of Intuitive Surgical from $420.00 to $430.00 and gave the stock a buy rating in a research note on Monday, April 8th. Five analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of Moderate Buy and a consensus target price of $396.17.

Intuitive Surgical Stock Performance

NASDAQ:ISRG opened at $366.34 on Friday. Intuitive Surgical has a one year low of $254.85 and a one year high of $403.76. The firm has a market cap of $129.85 billion, a price-to-earnings ratio of 66.13, a PEG ratio of 5.78 and a beta of 1.36. The firm’s fifty day moving average is $386.84 and its two-hundred day moving average is $343.10.

Intuitive Surgical (NASDAQ:ISRG) last posted its quarterly earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 EPS for the quarter, beating the consensus estimate of $1.40 by $0.10. Intuitive Surgical had a net margin of 27.16% and a return on equity of 13.27%. The company had revenue of $1.89 billion for the quarter, compared to analyst estimates of $1.87 billion. During the same period in the prior year, the company earned $1.00 earnings per share. The firm’s revenue was up 11.5% on a year-over-year basis. As a group, equities research analysts predict that Intuitive Surgical will post 4.93 earnings per share for the current fiscal year.

Insider Buying and Selling at Intuitive Surgical

In other Intuitive Surgical news, VP Marshall Mohr sold 108,790 shares of the stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $385.08, for a total value of $41,892,853.20. Following the completion of the sale, the vice president now owns 26,877 shares in the company, valued at approximately $10,349,795.16. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other news, SVP Mark Brosius sold 196 shares of the firm’s stock in a transaction that occurred on Tuesday, March 5th. The shares were sold at an average price of $400.00, for a total transaction of $78,400.00. Following the completion of the sale, the senior vice president now owns 1,842 shares in the company, valued at approximately $736,800. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Marshall Mohr sold 108,790 shares of the firm’s stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $385.08, for a total transaction of $41,892,853.20. Following the sale, the vice president now owns 26,877 shares of the company’s stock, valued at approximately $10,349,795.16. The disclosure for this sale can be found here. In the last quarter, insiders sold 248,418 shares of company stock worth $95,927,097. Insiders own 0.90% of the company’s stock.

Institutional Trading of Intuitive Surgical

Hedge funds and other institutional investors have recently made changes to their positions in the company. Baystate Wealth Management LLC increased its holdings in shares of Intuitive Surgical by 150.0% during the 4th quarter. Baystate Wealth Management LLC now owns 75 shares of the medical equipment provider’s stock worth $25,000 after buying an additional 45 shares during the last quarter. MCF Advisors LLC boosted its position in shares of Intuitive Surgical by 108.1% during the 4th quarter. MCF Advisors LLC now owns 77 shares of the medical equipment provider’s stock worth $26,000 after purchasing an additional 40 shares during the period. Able Wealth Management LLC purchased a new position in shares of Intuitive Surgical during the 4th quarter worth approximately $28,000. Atticus Wealth Management LLC boosted its position in shares of Intuitive Surgical by 85.4% during the 4th quarter. Atticus Wealth Management LLC now owns 89 shares of the medical equipment provider’s stock worth $30,000 after purchasing an additional 41 shares during the period. Finally, MeadowBrook Investment Advisors LLC purchased a new position in shares of Intuitive Surgical during the 4th quarter worth approximately $30,000. Institutional investors and hedge funds own 83.64% of the company’s stock.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.